Vor bio appoints eyal c. attar, m.d.

Cambridge, mass., oct. 12, 2022 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced that eyal c. attar, m.d., has joined vor bio as chief medical officer (cmo). dr. attar brings more than 20 years of demonstrated clinical experience to the position, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies.
VOR Ratings Summary
VOR Quant Ranking